Search

Genmab A-S

Открыт

2,140 -1.25

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

2142

Макс.

2181

Ключевые показатели

By Trading Economics

Доход

243M

295M

Продажи

259M

1.2B

P/E

Средняя по отрасли

26.302

56.597

Прибыль на акцию

34.85

Рентабельность продаж

25.541

Сотрудники

3,119

EBITDA

216M

431M

Рекомендации

By TipRanks

Рекомендации

Нейтрально

Прогноз на 12 месяцев

-1.49% downside

Дивиденды

By Acuity

Следующий отчет о доходах

5 нояб. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

18B

132B

Предыдущая цена открытия

2141.25

Предыдущая цена закрытия

2140

Genmab A-S График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

8 сент. 2026 г., 23:56 UTC

Compass Minerals International Inc shares are lower in after-market hours, with no specific news identified. Broader market expectations for an interest rate hike persist.

8 сент. 2026 г., 23:56 UTC

Pacific Biosciences of California Inc. shares are higher in after-market trading, despite fluctuations, and remain above their 20-day moving average.

8 сент. 2026 г., 23:56 UTC

NextDecade Corp shares gained slightly in after-market trading. The stock remains above its 20-day moving average amid broader economic influences.

8 сент. 2026 г., 23:56 UTC

Arrow Financial Corp shares are lower in after-market hours with no specific news identified. The stock has recovered from an initial decline.

8 сент. 2026 г., 23:56 UTC

Qualys Inc shares are lower in after-market trading amid broader market weakness. The stock has declined for three consecutive sessions.

8 сент. 2026 г., 23:56 UTC

Correlated Moves

Illinois Tool Works Inc shares are lower in after-market trading, reflecting broader industrial sector trends and influenced by declines in Lincoln Electric Holdings Inc.

8 сент. 2026 г., 23:56 UTC

PPL Corp shares are higher in after-market trading, reflecting broader market sentiment following a strong jobs report that raised interest rate hike expectations.

8 сент. 2026 г., 23:56 UTC

Correlated Moves

Samsara Inc shares are lower in after-market hours, influenced by ServiceTitan Inc's significant drop and broader market concerns over potential interest rate hikes.

8 сент. 2026 г., 23:56 UTC

News

Korn Ferry's Board declared a quarterly cash dividend of $0.55 per share, payable October 15. Shares traded roughly flat in after-market hours.

8 сент. 2026 г., 23:56 UTC

Mastercraft Boat Holdings Inc. shares were roughly flat in after-market hours, reflecting minimal price movement amid ongoing performance challenges.

8 сент. 2026 г., 23:56 UTC

Comcast Corp shares are lower in after-market trading, following a session low. Recent economic data has influenced market expectations for potential interest rate hikes.

8 сент. 2026 г., 23:56 UTC

Brown & Brown Inc shares are lower in after-market hours, reflecting broader market concerns over a potential interest rate hike following a strong jobs report.

8 сент. 2026 г., 23:56 UTC

Cytokinetics Inc shares are higher in after-market trading, reflecting broader market sentiment following a strong jobs report and rising interest rate expectations.

8 сент. 2026 г., 23:56 UTC

Social Media
News

Chevron Corp shares are higher in after-market hours following a report on declining OECD strategic petroleum reserves, which may impact oil prices and benefit the company.

8 сент. 2026 г., 23:52 UTC

Ovid Therapeutics Inc is higher in after-market trading, reflecting positive momentum since Tuesday's close and positioning above its 20-day moving average.

8 сент. 2026 г., 23:52 UTC

Cardinal Health Inc shares are lower in after-market hours, with volatility noted despite no specific company news or developments influencing the decline.

8 сент. 2026 г., 23:51 UTC

CVR Energy Inc shares are higher in after-market trading, recovering from earlier volatility. Rising crude oil prices may be influencing market dynamics.

8 сент. 2026 г., 23:51 UTC

Harley-Davidson Inc shares are higher in after-market trading, reflecting volatility amid rising crude oil prices and inflation concerns following a strong jobs report.

8 сент. 2026 г., 23:51 UTC

Huron Consulting Group Inc shares are lower in after-market trading, retracing from an earlier session high and remaining below the 20-day moving average.

8 сент. 2026 г., 23:51 UTC

Range Resources Corp shares are higher in after-market trading, buoyed by rising crude oil prices nearing $99 per barrel and a strong jobs report.

8 сент. 2026 г., 23:51 UTC

Gold Resource Corp shares are lower in after-market hours amid rising crude oil prices and inflation concerns ahead of the Federal Reserve meeting.

8 сент. 2026 г., 23:51 UTC

Brazil's Retail Sales MoM report on September 15, 2026, expected to reveal consumer spending trends and impact economic growth outlook.

8 сент. 2026 г., 23:51 UTC

South Korea's unemployment rate drops to 2.7% in August, signaling strong job growth and positive investor sentiment amidst global economic uncertainties.

8 сент. 2026 г., 23:51 UTC

Japan's July Machinery Orders Expected to Reflect Positive Capital Spending Trends Amidst Economic Recovery and Investor Optimism

8 сент. 2026 г., 23:51 UTC

Japan's Trade Balance Data Release on September 15, 2026: Market Braces for Persistent Deficits Amid Weak Yen and Geopolitical Tensions.

8 сент. 2026 г., 23:51 UTC

Japan's upcoming exports data release on September 15, 2026, is anticipated to reflect continued reliance on high-tech products amid positive economic indicators and rising real wages, despite global market uncertainties.

8 сент. 2026 г., 23:51 UTC

Ambarella Inc. showed unusual strength in after-market trading, advancing despite rising crude oil prices and inflation concerns. No specific news was identified for the move.

8 сент. 2026 г., 23:51 UTC

ETSY Inc. shares are higher in after-market trading, despite remaining below the 20-day moving average and near the lower end of the one-month range.

8 сент. 2026 г., 23:51 UTC

Shares of United Airlines Holdings Inc. are higher in after-market trading, though they remain below the 20-day moving average and near the one-month range low.

8 сент. 2026 г., 23:51 UTC

Illumina Inc shares are higher in after-market trading, showing notable activity and positioning above the 20-day moving average amid a lack of specific news.

Сравнение c конкурентами

Изменение цены

Genmab A-S Прогноз

Целевая цена

By TipRanks

-1.49% падение

Прогноз на 12 месяцев

Средняя 2,493.35 DKK  -1.49%

Максимум 3,320 DKK

Минимум 308.417 DKK

Основано на мнении 7 аналитиков Wall Street, спрогнозировавших целевые цены для Genmab A-S на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Нейтрально

7 ratings

3

Покупка

2

Удержание

2

Продажа

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Genmab A-S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
help-icon Live chat